TMD

Titan Medical to Report Year-End 2023 Financial Results on March 29, 2024

Retrieved on: 
Monday, March 4, 2024

TORONTO, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that the Company plans to issue its year-end 2023 financial results after the market closing on March 29, 2024.

Key Points: 

TORONTO, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that the Company plans to issue its year-end 2023 financial results after the market closing on March 29, 2024.

Titan Medical Announces Benchmark Electronics, Inc. Purported to Terminate Agreement

Retrieved on: 
Friday, December 1, 2023

TORONTO, Ontario, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has purported to terminate the agreement.

Key Points: 
  • TORONTO, Ontario, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has purported to terminate the agreement.
  • Titan did not receive delivery from Benchmark of manufactured Enos Surgical System units and disputes that Benchmark has grounds for the termination.
  • Titan has rejected Benchmark’s allegation that Titan breached the agreement.

Titan Medical Reports Operating and Financial Results for the Third Quarter 2023

Retrieved on: 
Thursday, November 2, 2023

TORONTO, Ontario, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • TORONTO, Ontario, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today financial results for the three and nine months ended September 30, 2023.
  • On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.
  • As of September, 30, 2023, Titan had cash of $8.9 million, compared to $3.3 million on December 31, 2022.
  • In addition, the Company has reduced its outstanding financial obligations to vendors by $5.3 million from the first quarter of 2023.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, PUBLISHES CASE STUDY DEMONSTRATING NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Thursday, October 26, 2023

PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects. The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.

Key Points: 
  • PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

Titan Medical Announces Change in Auditor

Retrieved on: 
Wednesday, October 18, 2023

TORONTO, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, announces that it has changed its auditor from BDO Canada LLP (the “Former Auditor”) to MNP LLP (the “Successor Auditor”) effective October 10, 2023.

Key Points: 
  • TORONTO, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, announces that it has changed its auditor from BDO Canada LLP (the “Former Auditor”) to MNP LLP (the “Successor Auditor”) effective October 10, 2023.
  • At the request of the Company, the Former Auditor resigned as auditor of the Company on October 10, 2023 and the board of directors of the Company appointed the Successor Auditor as the new auditor until the next annual general meeting of shareholders of the Company.
  • The Company’s board of directors and audit committee each approved the resignation of the Former Auditor and the appointment of the Successor Auditor in place of the Former Auditor; there were no “reportable events”, as the term is defined in National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), in connection with each of the Former Auditor’s audits of the Company which occurred prior to their resignation as auditors of the Company; and the Notice of Change of Auditor was approved by the Company’s board of directors.
  • In accordance with NI 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the audit committee and the board of directors and have been filed on SEDAR+.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, ANNOUNCE NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Tuesday, October 3, 2023

PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.

Key Points: 
  • PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • Standard treatment includes simply resting the jaw muscles and avoiding use, massage, physical therapy, medication management, and, when all else fails, surgery.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

CPI TMD TECHNOLOGIES PROJECT AWARDED MORE THAN £4 MILLION TO DEVELOP COMPACT, HIGH-PRECISION INERTIAL GUIDANCE SYSTEM

Retrieved on: 
Thursday, August 31, 2023

Under this contract, CPI TMD Technologies and its partners will develop exceptionally high-precision quantum-enabled positioning, navigation and timing systems that can be used to identify an object's exact position in time and space without the use of satellite signals.

Key Points: 
  • Under this contract, CPI TMD Technologies and its partners will develop exceptionally high-precision quantum-enabled positioning, navigation and timing systems that can be used to identify an object's exact position in time and space without the use of satellite signals.
  • This "quantum inertial sensor" will be based on CPI TMD Technologies' existing quantum technology, including the compact grating magneto-optical trap (gMOT) subsystems and Calcium Ion Frequency Source (CIFS) clock, which provides unprecedented precision and accuracy in timekeeping.
  • "As a manufacturer of microwave technologies, CPI TMD Technologies has long focused on finding innovative solutions to challenging requirements in the defence, communications and industrial markets and putting them into production.
  • CPI TMD Technologies' work on this multi-year contract will be carried out at its facilities in Hayes, Middlesex, England.

CPI TMD TECHNOLOGIES PROJECT AWARDED MORE THAN £4 MILLION TO DEVELOP COMPACT, HIGH-PRECISION INERTIAL GUIDANCE SYSTEM

Retrieved on: 
Thursday, August 31, 2023

Under this contract, CPI TMD Technologies and its partners will develop exceptionally high-precision quantum-enabled positioning, navigation and timing systems that can be used to identify an object's exact position in time and space without the use of satellite signals.

Key Points: 
  • Under this contract, CPI TMD Technologies and its partners will develop exceptionally high-precision quantum-enabled positioning, navigation and timing systems that can be used to identify an object's exact position in time and space without the use of satellite signals.
  • This "quantum inertial sensor" will be based on CPI TMD Technologies' existing quantum technology, including the compact grating magneto-optical trap (gMOT) subsystems and Calcium Ion Frequency Source (CIFS) clock, which provides unprecedented precision and accuracy in timekeeping.
  • "As a manufacturer of microwave technologies, CPI TMD Technologies has long focused on finding innovative solutions to challenging requirements in the defence, communications and industrial markets and putting them into production.
  • CPI TMD Technologies' work on this multi-year contract will be carried out at its facilities in Hayes, Middlesex, England.

NeurAxis Highlights Strength of its Board of Directors

Retrieved on: 
Thursday, August 24, 2023

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.

Key Points: 
  • CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
  • “We are fortunate to have a board with a depth of experience in relevant areas to NeurAxis, including medical device commercialization, commercial insurance, and finance.
  • “We are excited to have this strength at the board level as we continue to develop and drive adoption of our IB Stim Therapy™,” concluded Mr. Carrico.
  • The Company’s Board of Directors includes:
    Ms. Keyser has more than 20 years of experience in executive roles in population health.

EQS-News: AEQUITA SE & Co. KGaA : AEQUITA acquires TMD Friction Group from Nisshinbo

Retrieved on: 
Wednesday, August 23, 2023

Munich, 23 August 2023 - AEQUITA SE & Co. KGaA, a global industrial group headquartered in Munich, Germany, entered into a definitive agreement to acquire TMD Friction Group S.A. from Nisshinbo Holdings Inc.. TMD Friction is a globally leading manufacturer and distributor of brake friction materials for passenger cars, commercial vehicles, and industry applications.

Key Points: 
  • Munich, 23 August 2023 - AEQUITA SE & Co. KGaA, a global industrial group headquartered in Munich, Germany, entered into a definitive agreement to acquire TMD Friction Group S.A. from Nisshinbo Holdings Inc.. TMD Friction is a globally leading manufacturer and distributor of brake friction materials for passenger cars, commercial vehicles, and industry applications.
  • Based on a comprehensive selection process, Nisshinbo chose AEQUITA as the trusted partner to ensure TMD’s sustainable long-term development and future growth.
  • "We are very proud and honoured that Nisshinbo selected AEQUITA as the best owner for TMD,” said Christoph Himmel, Managing Partner of AEQUITA.
  • “TMD Friction is a great company and a significant addition to our automotive division, now recording sales of more than 2 billion euros.